Anagram Therapeutics

Anagram TherapeuticsAnagram Therapeutics
Anagram Therapeutics

Anagram Therapeutics

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Website
DR 172017ActiveNatick, USA
Rate
Advertise here

About

Anagram Therapeutics is a clinical-stage private biopharmaceutical company focused on improving the lives of individuals suffering from exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, pancreatic cancer, and other related disorders. The company is developing ANG003, an orally delivered recombinant enzyme therapy.
Frequently asked

What does Anagram Therapeutics do?

Anagram Therapeutics is a clinical-stage private biopharmaceutical company focused on improving the lives of individuals suffering from exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, pancreatic cancer, and other related disorders. The company is developing ANG003, an orally delivered recombinant enzyme therapy.

What is Anagram Therapeutics's revenue?

StartupHub estimates Anagram Therapeutics's annual revenue at $41.1M (range $12.9M to $125.0M, 35% confidence), based on comparable companies in the sector.

What is Anagram Therapeutics's valuation?

StartupHub estimates Anagram Therapeutics's effective valuation at $1.1B (range $712.5M to $1.7B, 24% confidence), based on comparable companies in the sector.

How much funding has Anagram Therapeutics raised?

Anagram Therapeutics has raised a total of $285M in funding. The most recent round on record is Investment.

Where is Anagram Therapeutics headquartered?

Anagram Therapeutics is headquartered in Natick, Massachusetts, USA.

When was Anagram Therapeutics founded?

Anagram Therapeutics was founded in 2017.

What industry does Anagram Therapeutics operate in?

Anagram Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery, Clinical Trials.

Comments

No comments yet. Be the first to share your take.